Cost effectiveness of fulvestrant as an additional endocrine step in the treatment sequence for hormone responsive advanced breast cancer

被引：0
|
作者：
Hirsch, M. W.
Gait, C.
Chambers, J.
机构：
[1] AstraZeneca UK Ltd, Macclesfield, Cheshire, England
[2] Mapi Values Ltd, Macclesfield, Cheshire, England
来源：
VALUE IN HEALTH | 2006年 / 9卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)63472-9
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
下载
收藏
页码：A288 / A288
页数：1
相关论文
共 50 条
  • [1] ECONOMIC EVALUATION OF FULVESTRANT (FASLODEX®) AS AN ADDITIONAL ENDOCRINE STEP IN THE TREATMENT SEQUENCE FOR HORMONE-RECEPTOR POSITIVE ADVANCED AND METASTATIC BREAST CANCER IN ISRAEL
    Greenberg, D.
    Rabinovich, M.
    Hirsch, M.
    VALUE IN HEALTH, 2009, 12 (03) : A46 - A46
  • [2] Insights Into the Place of Fulvestrant for the Treatment of Advanced Endocrine Responsive Breast Cancer
    Howell, Anthony
    Bergh, Jonas
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (30) : 4548 - 4550
  • [3] Fulvestrant injection (Faslodex) - Additional treatment for advanced breast cancer
    不详
    AMERICAN JOURNAL OF NURSING, 2002, 102 (08) : 24CCC - 24CCC
  • [4] Fulvestrant in the treatment of hormone receptor-positive advanced breast cancer - A cost-effective addition to the treatment sequence.
    Cameron, D. A.
    Camidge, D. R.
    Gait, C.
    Hirsch, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S231 - S232
  • [5] Endocrine treatment options for advanced breast cancer - the role of fulvestrant
    Robertson, JFR
    Come, SE
    Jones, SE
    Beex, L
    Kaufmann, M
    Makris, A
    Nortier, JWR
    Possinger, K
    Rutqvist, LE
    EUROPEAN JOURNAL OF CANCER, 2005, 41 (03) : 346 - 356
  • [6] Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer
    Oakman, Catherine
    Moretti, Erica
    Santarpia, Libero
    Di Leo, Angelo
    FUTURE ONCOLOGY, 2011, 7 (02) : 173 - 186
  • [7] COST EFFECTIVENESS OF FULVESTRANT 500 MG IN ENDOCRINE THERAPY-NAIVE WOMEN WITH HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER IN THE UK
    Livings, C.
    Jones, N.
    Bertranou, E.
    Large, S.
    Phelps, H.
    Ekman, M.
    Telford, C.
    VALUE IN HEALTH, 2017, 20 (09) : A435 - A435
  • [8] Fulvestrant: Expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer
    Chia, Stephen
    Gradishar, William
    BREAST, 2008, 17 : S16 - S21
  • [9] Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer
    Cameron, D. A.
    Camidge, D. R.
    Oyee, J.
    Hirsch, M.
    BRITISH JOURNAL OF CANCER, 2008, 99 (12) : 1984 - 1990
  • [10] Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer
    D A Cameron
    D R Camidge
    J Oyee
    M Hirsch
    British Journal of Cancer, 2008, 99 : 1984 - 1990
12345